Background/Aim: Surgical resection remains the mainstay of treatment for hepatocellular
carcinoma (HCC). However, reducing the risk of postoperative recurrence is urgently …

Background. Sorafenib is a multikinase inhibitor currently used in the treatment of
hepatocellular carcinoma, renal cell carcinoma and thyroid cancer. Objectives. The literature …

Background Hepatocellular carcinoma (HCC) has a high incidence and mortality.
Radiotherapy and sorafenib have proven effective for HCC. Here, we investigated whether …

Sorafenib increases survival of patients with advanced hepatocellular carcinoma (HCC) by
inhibiting RAF kinase and receptor tyrosine kinase activity, but involvement of sorafenib in …

Aim Hepatocellular carcinoma (HCC) is the most common liver malignancy and the second
leading cause of cancer‐related deaths in the world. Sorafenib is the first‐line treatment of …

Background/Aim: Sorafenib is a multikinase inhibitor approved as a first-line therapy for
hepatocellular carcinoma. This study examined the sorafenib resistance mechanism …

Purpose: Novel therapeutic strategies are needed to prevent the tumor recurrence or
metastasis after liver transplantation for hepatocellular carcinoma (HCC). This study was to …

Methods BEL-7402 cells were treated with sorafenib or paclitaxel alone or in three different
schedules: sorafenib was give prior to, after, or simultaneously with paclitaxel. The half …

Purpose: The purpose of this study was to determine the impact of sorafenib on
PI3K/AKT/mTOR signaling pathway and to further define its mechanism for treating …

Purpose To investigate the optimal starting time point of sorafenib therapy in suppressing
the tumor-promoting effects of VEGF up-regulation, which is frequently found after local …